Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Verano Holdings
VRNO
Verano Holdings
Cannabis Competition And Credit Risk Will Erode Margins Yet Stabilize
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
10 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$1.47
39.1% overvalued
intrinsic discount
10 Aug
CA$2.05
Loading
1Y
-62.0%
7D
78.3%
Author's Valuation
CA$1.5
39.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$1.5
39.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-346m
921m
2018
2020
2022
2024
2025
2026
2028
Revenue US$884.5m
Earnings US$25.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
2.93%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.39%
Calculation
US$25.68m
Earnings '28
x
21.01x
PE Ratio '28
=
US$539.56m
Market Cap '28
US$539.56m
Market Cap '28
/
412.08m
No. shares '28
=
US$1.31
Share Price '28
US$1.31
Share Price '28
Discounted to 2025 @ 6.93% p.a.
=
US$1.07
Fair Value '25
US$1.07
Fair Value '25
Converted to CAD @ 1.3757 USD/CAD Exchange Rate
=
CA$1.47
Fair Value '25
